These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18447599)

  • 1. Axitinib for renal cell carcinoma.
    Sonpavde G; Hutson TE; Rini BI
    Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib for the management of metastatic renal cell carcinoma.
    Escudier B; Gore M
    Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    Goldstein R; Pickering L; Larkin J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib (Inlyta) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
    [No Abstract]   [Full Text] [Related]  

  • 6. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
    Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
    Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
    Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
    Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib: a review in advanced renal cell carcinoma.
    Keating GM
    Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 19. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
    Yang LP; McKeage K
    Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
    Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
    Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.